ES2939494T3 - Conjugados de fármaco anticuerpo que comprenden derivados de ecteinascidina - Google Patents

Conjugados de fármaco anticuerpo que comprenden derivados de ecteinascidina Download PDF

Info

Publication number
ES2939494T3
ES2939494T3 ES19790550T ES19790550T ES2939494T3 ES 2939494 T3 ES2939494 T3 ES 2939494T3 ES 19790550 T ES19790550 T ES 19790550T ES 19790550 T ES19790550 T ES 19790550T ES 2939494 T3 ES2939494 T3 ES 2939494T3
Authority
ES
Spain
Prior art keywords
group
alkylene
antibody
substituted
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19790550T
Other languages
English (en)
Spanish (es)
Inventor
Marchante Maria Del Carmen Cuevas
Solloso Andres Francesch
Lozano Alfonso Latorre
Barrasa Valentin Martinez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmamar SA filed Critical Pharmamar SA
Application granted granted Critical
Publication of ES2939494T3 publication Critical patent/ES2939494T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES19790550T 2018-10-25 2019-10-25 Conjugados de fármaco anticuerpo que comprenden derivados de ecteinascidina Active ES2939494T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382759 2018-10-25
PCT/EP2019/079188 WO2020084115A1 (en) 2018-10-25 2019-10-25 Antibody drug conjugates comprising ecteinascidin derivatives

Publications (1)

Publication Number Publication Date
ES2939494T3 true ES2939494T3 (es) 2023-04-24

Family

ID=64426824

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19790550T Active ES2939494T3 (es) 2018-10-25 2019-10-25 Conjugados de fármaco anticuerpo que comprenden derivados de ecteinascidina

Country Status (37)

Country Link
US (1) US20230012681A1 (https=)
EP (1) EP3870234B1 (https=)
JP (1) JP7629400B2 (https=)
KR (1) KR20210086669A (https=)
CN (1) CN113226377B (https=)
AR (1) AR117657A1 (https=)
AU (1) AU2019368687B2 (https=)
BR (1) BR112021007718A2 (https=)
CA (1) CA3117268C (https=)
CL (1) CL2021001039A1 (https=)
CO (1) CO2021006838A2 (https=)
DK (1) DK3870234T3 (https=)
EA (1) EA202191131A1 (https=)
EC (1) ECSP21035414A (https=)
ES (1) ES2939494T3 (https=)
FI (1) FI3870234T3 (https=)
HR (1) HRP20230275T1 (https=)
HU (1) HUE061606T2 (https=)
IL (1) IL282577B2 (https=)
JO (1) JOP20210083B1 (https=)
LT (1) LT3870234T (https=)
MA (1) MA59661B1 (https=)
MD (1) MD3870234T2 (https=)
MX (1) MX2021004746A (https=)
MY (1) MY206221A (https=)
PH (1) PH12021550930A1 (https=)
PL (1) PL3870234T3 (https=)
PT (1) PT3870234T (https=)
RS (1) RS64068B1 (https=)
SA (1) SA521421855B1 (https=)
SG (1) SG11202104154WA (https=)
SI (1) SI3870234T1 (https=)
SM (1) SMT202300076T1 (https=)
TW (1) TWI824043B (https=)
UA (1) UA129803C2 (https=)
WO (1) WO2020084115A1 (https=)
ZA (1) ZA202103478B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102491180B1 (ko) * 2017-04-27 2023-01-20 파르마 마르 에스.에이. 항종양 화합물
WO2021218896A1 (zh) * 2020-04-26 2021-11-04 江苏恒瑞医药股份有限公司 海鞘素类衍生物及其制备方法与医药用途
US11124568B1 (en) * 2020-08-19 2021-09-21 Vitruviae LLC CD3/CD25 antibodies for neuro-immune diseases
IL308389A (en) * 2021-05-19 2024-01-01 Pharma Mar Sa Dosing regimens for acubactadine
KR102625740B1 (ko) * 2021-07-15 2024-01-17 주식회사 새한비엠 폐수지 재료 및 미네랄 바인더를 이용한 단열차음재의 제조 방법 및 그 단열차음재
WO2024091437A1 (en) * 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
AU2024210894A1 (en) * 2023-01-17 2025-07-17 Adcytherix Sas Ecteinascidin derivative antibody drug conjugates
WO2024186263A1 (en) 2023-03-07 2024-09-12 Axcynsis Therapeutics Pte. Ltd. Antibody-drug conjugates comprising trabectedin and lurbinectedin derivatives
CN118878690B (zh) * 2023-11-28 2026-01-09 南京大学 一种抗地高辛纳米抗体的制备及其应用
TW202547489A (zh) * 2024-04-30 2025-12-16 西班牙商瑪製藥股份有限公司 化合物ia於包括與阿替利珠單抗的組合療法之癌症的治療中之用途
TW202547488A (zh) * 2024-04-30 2025-12-16 西班牙商瑪製藥股份有限公司 於癌症的治療中之化合物Ｉａ和拓樸異構酶Ｉ抑制劑的組合
WO2025233522A1 (en) * 2024-05-10 2025-11-13 Pharma Mar, S.A. Synthetic process for an ecteinascidin

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
KR20070053214A (ko) * 2004-08-26 2007-05-23 니콜라스 피라말 인디아 리미티드 신규 생분해성 링커를 함유하는 프로드럭
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド 抗体薬剤結合体および方法
CA3000520C (en) 2005-08-24 2023-04-04 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
GB201506405D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
KR102491180B1 (ko) * 2017-04-27 2023-01-20 파르마 마르 에스.에이. 항종양 화합물
CN115427081B (zh) * 2020-04-21 2025-12-09 法马马有限公司 药物抗体共轭物

Also Published As

Publication number Publication date
SA521421855B1 (ar) 2023-12-11
ZA202103478B (en) 2022-12-21
UA129803C2 (uk) 2025-08-06
JOP20210083B1 (ar) 2024-12-22
HUE061606T2 (hu) 2023-07-28
ECSP21035414A (es) 2021-06-30
SG11202104154WA (en) 2021-05-28
CN113226377A (zh) 2021-08-06
EA202191131A1 (ru) 2021-10-15
WO2020084115A1 (en) 2020-04-30
FI3870234T3 (fi) 2023-03-23
MA59661B1 (fr) 2023-03-31
MD3870234T2 (ro) 2023-05-31
HRP20230275T1 (hr) 2023-04-28
AR117657A1 (es) 2021-08-25
PH12021550930A1 (en) 2021-11-22
BR112021007718A2 (pt) 2021-08-10
JOP20210083A1 (ar) 2023-01-30
EP3870234B1 (en) 2022-12-21
CA3117268C (en) 2023-11-21
TWI824043B (zh) 2023-12-01
CN113226377B (zh) 2022-10-18
IL282577B1 (en) 2023-06-01
KR20210086669A (ko) 2021-07-08
SI3870234T1 (sl) 2023-06-30
IL282577A (en) 2021-06-30
EP3870234A1 (en) 2021-09-01
MX2021004746A (es) 2021-08-24
CA3117268A1 (en) 2020-04-30
RS64068B1 (sr) 2023-04-28
MY206221A (en) 2024-12-04
AU2019368687A1 (en) 2021-06-10
CO2021006838A2 (es) 2021-06-10
SMT202300076T1 (it) 2023-05-12
DK3870234T3 (da) 2023-03-20
JP2022512830A (ja) 2022-02-07
US20230012681A1 (en) 2023-01-19
TW202034957A (zh) 2020-10-01
AU2019368687B2 (en) 2025-10-23
LT3870234T (lt) 2023-03-27
CL2021001039A1 (es) 2021-10-01
PL3870234T3 (pl) 2023-04-24
JP7629400B2 (ja) 2025-02-13
PT3870234T (pt) 2023-03-06
IL282577B2 (en) 2023-10-01

Similar Documents

Publication Publication Date Title
ES2939494T3 (es) Conjugados de fármaco anticuerpo que comprenden derivados de ecteinascidina
ES2778045T3 (es) Conjugados fármaco-anticuerpo
CN115427081B (zh) 药物抗体共轭物
CN114615999B (zh) 药物抗体偶联物
EA046742B1 (ru) Конъюгаты антитело-лекарственное средство, содежащие производные эктеинасцидина
HK40053316A (en) Antibody drug conjugates comprising ecteinascidin derivatives
HK40053316B (en) Antibody drug conjugates comprising ecteinascidin derivatives
HK40067834A (en) Drug antibody conjugates
HK40067834B (en) Drug antibody conjugates